Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTLNASDAQ:CLRBNASDAQ:MBRXNASDAQ:ME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$1.04+1.0%$0.98$0.82▼$1.59$3.41M1.17134,072 shs23,155 shsCLRBCellectar Biosciences$0.31-0.9%$0.31$0.22▼$3.51$14.29M0.671.13 million shs396,610 shsMBRXMoleculin Biotech$1.06-4.5%$1.05$0.40▼$5.47$14.84M2.191.45 million shs247,973 shsME23andMe$0.50-35.3%$1.17$0.53▼$12.76$13.36M1.191.22 million shs29.28 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences0.00%+9.04%+10.64%-13.33%-22.38%CLRBCellectar Biosciences0.00%+3.68%-7.41%+14.43%-89.77%MBRXMoleculin Biotech0.00%+21.16%+1.92%-37.03%-77.11%ME23andMe0.00%0.00%-17.86%-85.13%-94.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTLArtelo Biosciences2.3131 of 5 stars3.82.00.00.02.40.01.3CLRBCellectar Biosciences1.6797 of 5 stars3.33.00.00.01.60.00.6MBRXMoleculin Biotech2.9674 of 5 stars3.55.00.00.02.50.01.3ME23andMe0.3546 of 5 stars0.01.00.00.01.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTLArtelo Biosciences 3.50Strong Buy$5.50428.85% UpsideCLRBCellectar Biosciences 2.50Moderate Buy$12.503,932.26% UpsideMBRXMoleculin Biotech 3.00Buy$6.00466.04% UpsideME23andMe 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ARTL, CLRB, ME, and MBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/25/2025MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$4.003/24/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/22/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)3/7/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)3/4/2025ARTLArtelo BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/3/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.002/27/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.002/19/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)2/12/2025MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold2/1/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTLArtelo BiosciencesN/AN/AN/AN/A$4.12 per shareN/ACLRBCellectar BiosciencesN/AN/AN/AN/A($0.96) per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A$11.70 per shareN/AME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTLArtelo Biosciences-$9.29M-$3.05N/AN/AN/AN/A-104.59%-94.06%5/12/2025 (Estimated)CLRBCellectar Biosciences-$42.77M-$1.33N/AN/AN/AN/AN/A-191.22%5/13/2025 (Estimated)MBRXMoleculin Biotech-$29.77MN/A0.00N/AN/AN/A-157.44%-97.16%5/9/2025 (Estimated)ME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/ALatest ARTL, CLRB, ME, and MBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CLRBCellectar Biosciences-$0.17N/AN/AN/AN/AN/A5/12/2025Q1 2025ARTLArtelo Biosciences-$0.13N/AN/AN/AN/AN/A5/9/2025Q1 2025MBRXMoleculin Biotech-$0.71N/AN/AN/AN/AN/A3/3/2025Q4 2024ARTLArtelo Biosciences-$0.74-$1.17-$0.43-$1.17N/AN/A1/28/2025Q3 2025ME23andMeN/A-$1.02N/A-$1.73N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTLArtelo BiosciencesN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTLArtelo BiosciencesN/A7.157.15CLRBCellectar BiosciencesN/A1.771.77MBRXMoleculin BiotechN/A2.082.08ME23andMeN/A1.050.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTLArtelo Biosciences0.87%CLRBCellectar Biosciences16.41%MBRXMoleculin Biotech15.52%ME23andMe36.10%Insider OwnershipCompanyInsider OwnershipARTLArtelo Biosciences0.83%CLRBCellectar Biosciences3.70%MBRXMoleculin Biotech1.90%ME23andMe26.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTLArtelo Biosciences53.28 million3.20 millionNot OptionableCLRBCellectar Biosciences1046.08 million44.38 millionOptionableMBRXMoleculin Biotech2014.00 million3.86 millionNot OptionableME23andMe77026.83 million19.77 millionNot OptionableARTL, CLRB, ME, and MBRX HeadlinesRecent News About These CompaniesHow 23andMe's bankruptcy led to a run on the gene bankApril 26 at 11:46 AM | northcountrypublicradio.org23andMe (NASDAQ:ME) Stock Price Down 35.3% - Time to Sell?April 26 at 3:15 AM | americanbankingnews.com23andMe—and who else?April 24, 2025 | bc.eduAGs Want Privacy Ombudsman in 23andMe BankruptcyApril 24, 2025 | law.com23andMe says ‘independent’ person to guide DNA decisions is important in its bankruptcy caseApril 23, 2025 | columbian.com23andMe Data Breach Class Asks Bankruptcy Court for Group ClaimApril 23, 2025 | news.bloomberglaw.com23andMe bankruptcy sale may need national security reviewApril 23, 2025 | reuters.comCan I delete my 23andMe DNA data? Here’s everything Canadians need to know before the DNA data auction in MayApril 22, 2025 | thespec.comTexas AG Ken Paxton Seeks to Protect Genetic Privacy Amidst 23andMe Bankruptcy CaseApril 22, 2025 | hoodline.comBankrupt 23andMe faces growing questions over data privacyApril 22, 2025 | cfodive.com23andMe says 'independent' person to guide DNA decisions is important in its bankruptcy caseApril 22, 2025 | stltoday.comCoreWeave wants quarter-million bucks back from 23andMeApril 21, 2025 | bizjournals.com23andMe, Inc.: 23andMe Provides Update Regarding Court-Supervised Sale ProcessApril 21, 2025 | finanznachrichten.de23andWho? The fate of your DNA data after the 23andMe bankruptcyApril 21, 2025 | jdsupra.comCongress to investigate 23andMe's handling of sensitive dataApril 20, 2025 | msn.comCongress has questions about 23andMe bankruptcyApril 20, 2025 | techcrunch.comFeds may want a say in 23andMe bankruptcy court sale of genetic dataApril 19, 2025 | bizjournals.comCongress Is Investigating 23andMe’s Handling of Personal DataApril 19, 2025 | gizmodo.comUS Says 23andMe Deal Could Prompt National Security ReviewApril 17, 2025 | msn.comCongressmen sound alarm over data privacy following 23andMe bankruptcyApril 17, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeat3 Stocks Near 52-Week Lows With Strong Rebound PotentialBy Gabriel Osorio-Mazilli | March 31, 2025View 3 Stocks Near 52-Week Lows With Strong Rebound PotentialGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to BenefitARTL, CLRB, ME, and MBRX Company DescriptionsArtelo Biosciences NASDAQ:ARTL$1.04 +0.01 (+0.97%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.02 -0.02 (-1.92%) As of 04/25/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Cellectar Biosciences NASDAQ:CLRB$0.31 0.00 (-0.93%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.31 0.00 (0.00%) As of 04/25/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Moleculin Biotech NASDAQ:MBRX$1.06 -0.05 (-4.50%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.10 +0.04 (+4.25%) As of 04/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.23andMe NASDAQ:ME$0.50 -0.27 (-35.32%) Closing price 03/28/2025Extended Trading$0.50 0.00 (0.00%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
